Q2 2026 13F · SEC CIK 2104501
Remedium Capital Partners, LLC
Institutional asset managerFiled 2026-08-07 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $451.6M
- Reported positions
- 6
- Holdings vs S&P 500, 3 yrs
- —
- Assets under management
- $319.0M
Remedium Capital Partners, LLC is an institutional asset manager that reported 6 positions worth $451.6M in its Q2 2026 13F, filed 2026-08-07. Its largest holdings were Oruka Therapeutics Inc (ORKA, 33.0%), Spyre Therapeutics (SYRE, 28.8%), Apogee Therapeutics Inc (APGE, 17.2%).
Remedium Capital Partners, LLC holdings all 6 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| ORKAOruka Therapeutics Inc | 33.0% | +0.0% | $149.0M |
| SYRESpyre Therapeutics | 28.8% | +0.5% | $130.0M |
| APGEApogee Therapeutics Inc | 17.2% | +0.5% | $77.9M |
| GLTODamora Therapeutics Inc | 11.8% | +0.0% | $53.2M |
| 008064206Jade Biosciences Inc | 7.8% | +0.0% | $35.1M |
| CBIOCrescent Biopharma Inc | 1.4% | — | $6.5M |
What Remedium Capital Partners, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- CBIO Crescent Biopharma Inc1.4% of 13F
Added to
No position grew by more than 5%.
Reduced
No position shrank by more than 5%.
Sold out
- GLYC Crescent Biopharma Inc.was 2.4%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- —
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $451.6M | 6 |
| Q1 2026 | $281.2M | 6 |
| Q4 2025 | $170.2M | 6 |
Questions about Remedium Capital Partners, LLC's portfolio
What stocks does Remedium Capital Partners, LLC own?
Remedium Capital Partners, LLC's latest 13F, for Q2 2026 and filed Aug 7, 2026, lists 6 positions worth $451.6M. The largest are Oruka Therapeutics Inc (ORKA) at 33.0%, Spyre Therapeutics (SYRE) at 28.8%, Apogee Therapeutics Inc (APGE) at 17.2%, Damora Therapeutics Inc (GLTO) at 11.8% and Jade Biosciences Inc at 7.8%.
What did Remedium Capital Partners, LLC buy last quarter?
In Q2 2026, Remedium Capital Partners, LLC added a new position in Crescent Biopharma Inc (CBIO), compared with its Q1 2026 filing.
What did Remedium Capital Partners, LLC sell last quarter?
In Q2 2026, Remedium Capital Partners, LLC sold all of Crescent Biopharma Inc. (GLYC), compared with its Q1 2026 filing.
When is Remedium Capital Partners, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Remedium Capital Partners, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Remedium Capital Partners, LLC manage?
Remedium Capital Partners, LLC reported $319.0M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $451.6M.